At the 1- and 2-year follow-up, GEE analyses of AD patients revealed that high levels of plasma clusterin at baseline were associated with a significantly larger decrease in MMSE compared with low levels of plasma clusterin (after adjustment for multiple covariate factors). This evidence concerns the gene CLU and Alzheimer disease.